CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Total revenues	$ 431,516	$ 2,053,457	$ 1,617,508	$ 3,716,247
Cost of revenues	154,804	270,883	566,417	557,508
Operating expenses:
Selling, general and administrative	2,589,042	2,407,223	7,247,999	8,018,516
Research and development	814,599	719,668	2,082,043	2,080,610
Depreciation and amortization	61,865	87,315	203,469	320,039
Total operating expenses	3,465,506	3,214,206	9,533,511	10,419,165
LOSS FROM OPERATIONS	(3,188,794)	(1,431,632)	(8,482,420)	(7,260,426)
Other (expense) income:
Interest expense (including related parties interest of $26,267 and $75,577 for the three and six months ended June 30, 2019, respectively)	(28,624)	(38,177)	(86,811)	(107,206)
Other expense, net	(72,694)	(8,102)	(334,527)	(31,356)
Loss before provision for income taxes	(3,290,112)	(1,477,911)	(8,903,758)	(7,398,988)
Provision for income taxes	0	0	0	0
NET LOSS	(3,290,112)	(1,477,911)
Less: Net loss (income) attributable to noncontrolling interest	662		(528)
NET LOSS attributable to Applied DNA Sciences, Inc.	(3,289,450)	(1,477,911)	(8,904,286)	(7,398,988)
Deemed dividend related to warrant modifications			(2,842)
NET LOSS applicable to common stockholders	$ (3,289,450)	$ (1,477,911)	$ (8,907,128)	$ (7,398,988)
Net loss per share applicable to common stockholders-basic and diluted	$ (0.72)	$ (1.55)	$ (2.54)	$ (8.46)
Weighted average shares outstanding-basic and diluted (in shares)	4,577,997	952,835	3,512,149	874,272
Product
Revenues:
Total revenues	$ 56,911	$ 392,599	$ 492,582	$ 885,736
Service
Revenues:
Total revenues	$ 374,605	$ 1,660,858	$ 1,124,926	$ 2,830,511